In a preclinical study, Vilgelm et al. showed that co-treatment with the CDK4/6 inhibitor ribociclib and the MDM2 antagonist nutlin-3a effectively overcame intrinsic resistance to CDK4/6 inhibition in melanoma patient-derived xenograft (PDX) models [104]. Here, CDK4 is linked to melanoma.